Colforsin (Forskolin, HL 362)

For research use only. Not for use in humans.

目录号:S2449 别名: Coleonol, Colforsin 中文名称:佛司可林

Colforsin (Forskolin, HL 362) Chemical Structure

CAS No. 66575-29-9

Colforsin (Forskolin, HL 362, Coleonol, Colforsin)在各种各样细胞类型中,是一种普遍存在的真核细胞腺苷酸环化酶(AC)激活剂,在细胞生理学研究中,通常用来提高cAMP水平。Forskolin 还可激发 PXRFXR的活性而诱导自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1144.16 现货
RMB 903.37 现货
RMB 3029.97 现货
RMB 4679.71 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Colforsin (Forskolin, HL 362)发表文献91篇:

产品安全说明书

cAMP抑制剂选择性比较

生物活性

产品描述 Colforsin (Forskolin, HL 362, Coleonol, Colforsin)在各种各样细胞类型中,是一种普遍存在的真核细胞腺苷酸环化酶(AC)激活剂,在细胞生理学研究中,通常用来提高cAMP水平。Forskolin 还可激发 PXRFXR的活性而诱导自噬。
靶点
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外研究

Forskolin可以使膜,细胞或组织制备液中cAMP含量上升。Forskolin 不仅可以活化AC 而且可以与某些其它蛋白相互作用,包括葡萄糖转运蛋白和离子通道。Forskolin能够促进9种不同独立AC形式的活化,虽然对AC9效率有点低,这可以用于提供一种鉴定和量化G蛋白 (Gs)–AC复合物高亲和性结合位点的方法。G蛋白偶联受体活化G蛋白有助于细胞中Forskolin刺激的cAMP 产生,因为 G蛋白-Forskolin对AC活性有增强作用[1]。Forskolin在不与细胞表面受体相互作用前提下刺激腺苷酸环化酶活性。在脂肪细胞中Forskolin's促进 cAMP产生进而可以抑制嗜碱性粒细胞和肥大细胞脱颗粒作用以及组胺释放,降低血压、眼内压,抑制血小板聚集,促进血管舒张,支气管扩张和甲状腺激素分泌,刺激脂肪分解。Forskolin 抑制血小板活化因子 (PAF)的结合, 这种抑制不依赖于cAMP形成可能是 Forskolin's 直接作用于 PAF或者通过干扰PAF与它的受体结合实现的。Forskolin似乎对多种膜转运蛋白也有效果并且可以抑制脂肪细胞,红细胞,血小板,和其他细胞中的葡萄糖运输。Forskolin也被用于治疗青光眼[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29  Mn;zRZBweHSxc3nzJGF{e2G7 MkfOOFDDqM7:TR?= M4j4UVQ5yqCq M2rNVWROW09? M4LtRYlv\HWlZYOgZ4hidmenczDpckB1cGVicHjvd5Bpd3K7bHH0bY9vKHO2YYT1d{Bw\iCSUELBJJRiemendIO= NELXS3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
SW480 NYP6cZlrSXCxcITvd4l{KEG|c3H5 MYG0NOKh|ryP NYm2SZc{PDkEoHi= MVLEUXNQ NH;VUZVqdmS3Y3XzJINp[W6pZYOgbY4hfGinIIDoc5NxcG:{eXzheIlwdiC|dHH0eZMhd2ZiUGCyRUB1[XKpZYTz MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
HT-29  MWfBdI9xfG:|aYOgRZN{[Xl? M3jMXFQxyqEQvF2= M13ieFQ5yqCq NFnDT4VFVVOR NXTxOFBMcW6mdXPld{BidiCjY4TpeoF1cW:wIH;mJINie3Cjc3WgN{84 MlHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 NYTUUYp3SXCxcITvd4l{KEG|c3H5 NUf5UplnPDEEoN88US=> NIr0S281QMLiaB?= MnTySG1UVw>? M2rOTYlv\HWlZYOgZY4h[WO2aY\heIlwdiCxZjDjZZNx[XOnIEOvOy=> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
HT-29  NYPMW4xXTnWwY4Tpc44hSXO|YYm= NXTKPHlEPDEEoN88US=> MWm3JIQ> M{m5N2ROW09? NFfPe5Jz\WS3Y3XzJINwdG:wb4PwbIVz\SCob4LtZZRqd25iY3HwZYJqdGm2edMg MnvmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 NWPFc3czTnWwY4Tpc44hSXO|YYm= NYj3OVhLPDEEoN88US=> M3vqS|ch\A>? Mlq5SG1UVw>? NUDm[ppUemWmdXPld{Bkd2yxbn;zdIhmemViZn;ycYF1cW:wIHPhdIFjcWyrdIpCpC=> NEDESHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
HT-29  MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XQO|QxyqEQvF2= NH7YN4UxNTd{IHi= Mk\DSG1UVw>? NWPLTok1cW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? MojhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSyOZdWPDEEoN88US=> MX[wMVczKGh? M2K4UWROW09? Ml7RbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> MmXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
HT-29  NVH4ZmptTnWwY4Tpc44hSXO|YYm= NYTWbGVWPDEEoN88US=> Ml\yOFjDqGh? MkLrSG1UVw>? Mm\SZYN1cX[jdHXzJHBROkF? MlizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 M13tdGZ2dmO2aX;uJGF{e2G7 MW[0NOKh|ryP NYr4e4hLPDkEoHi= MU\EUXNQ M1nrNIFkfGm4YYTld{BRWDKD M2rtNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
C6 MkC3SpVv[3Srb36gRZN{[Xl? MYSxNEDPxE4EoB?= MmrRNlAhdWmw M3vCZ4lv[3KnYYPld{BkSU2SIHHjZ5VufWyjdHnvci=> Ml;QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkm0NVcoRjJ3ME[5OFE4RC:jPh?=
Huh-7 MWjGeY5kfGmxbjDBd5NigQ>? M3rqZVAuOjBizszN MWeyJIjDqA>? NXvWWW9EemW|dXz0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KGmwY4LlZZNmKGmwIHOtUZlkKGW6cILld5Nqd25iYYSgeIhmKHC{b4TlbY4h[W6mIH3SUmEhdGW4ZXzz NILRO2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVg{PCd-MkWxNFk5OzR:L3G+
THP-1  M{K0PGZ2dmO2aX;uJGF{e2G7 MnO2NU8yOCEQvF2= M3PmU|LDqGh? NVv4XYNrTE2VT9Mg MYLzeZBxemW|c3XzJG1EWC1zIIDyc4R2[3Srb39CpC=> NWjhfIxXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVQ5QDJpPkK1NVU1QDh{PD;hQi=>
BeWo  NU\QdG9lTnWwY4Tpc44hSXO|YYm= NEewNlgzOCEEtV2= NUDOeY1WPDhiaB?= NHzOVpJFVVORwrC= NWC2WlVRcW6mdXPld{Bk\WyuIH\1d4lwdg>? Mn\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzOES0O|coRjJ3MUi0OFc4RC:jPh?=
ventricular cardiomyocytes  NYTsT3l7TnWwY4Tpc44hSXO|YYm= MUCwMlAyNTFyIN88US=> MUnleo9s\XNiYX6gbY5wfHKxcHnjJJJme3CxboPlJFEzOMLzMUWlJIFjd3[nIHLhd4FtKHerdHigZY4hTUN3MNMgc4YhOi5{INM1US=> M2HaN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkCzNVE{Lz5{NUKwN|EyOzxxYU6=
ventricular cardiomyocytes  NGrlbWtHfW6ldHnvckBCe3OjeR?= MkS5NE4xOS1zMDFOwG0> NXWxRYc{cW6lcnXhd4V{KCClQV3QJIFk[3WvdXzheIlwdg>? M4DSeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkCzNVE{Lz5{NUKwN|EyOzxxYU6=
MIN6  MXPGeY5kfGmxbjDBd5NigQ>? M2D2fVExKM7:TdMg M1HpWFMhcA>? M3[2W4lv[3KnYYPld{BFOyCvUl7BJIV5eHKnc4Ppc44> MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ2MUGyOEc,OjV{NEGxNlQ9N2F-
L6 NE[1eIRHfW6ldHnvckBCe3OjeR?= MmXtOFAhyrWP NXyyO5JLOjRiaB?= MYjpcohq[mm2czDEUWgyNWmwZIXj[YQhSWu2IHHjeIl3[XSrb36= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ2N{W1NEc,OjV{NEe1OVA9N2F-
HEK‐CFTR Mn\sSpVv[3Srb36gRZN{[Xl? M33BTFLjiJN3MNMg{txO NVLtPFkyOC1zMjDtbY4> MnnrSG1UV8Li MY\pcoR2[2W|IHGg[I9{\eLCkHTldIVv\GWwdDDpc4Rq\GViZX\mcJV5yqB? MkjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkOyNFcoRjJ3Mk[zNlA4RC:jPh?=
SK-N-SH MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXWxNEDPxE4EoB?= NI\IVFQ1QCCq MUHlcohidmOnczDTT{1PNVOKIH7leZJw[myjc4TvcYEh[2WubDD2bYFjcWyrdIm= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4NkC2N{c,OjV{Nk[wOlM9N2F-
SK-N-AS  M{i4XmZ2dmO2aX;uJGF{e2G7 MVWxNEDPxE4EoB?= MkX2NVAwOzBxNkCgcYlv MkHibY5kemWjc3XzJIxmfmWuczDv[kBxNc7{LXPheIVvcW5iKIPldlY4PSliYX7kJIlv\HWlZYOgZYNkfW23bHH0bY9vKG:oIICt{tIu[2G2ZX7pckApe2W{Nke1LUBqdiBqcHXybUlvfWOuZXHyJJJm\2mxboO= MlXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{Nk[wOlMoRjJ3Mk[2NFY{RC:jPh?=
SK-N-AS  MV\GeY5kfGmxbjDBd5NigQ>? NXK2TlE6OTBizszNxsA> NGPoOWQ{OCCvaX6= NHfreJhqdmS3Y3XzJJBpd3OyaH;yfYxifGmxbjDv[kDPui2lYYTlcolvKCi|ZYK2O|UqNCCyLVfTT|PPuiBqc3XyPUkh[W6mIHPvcoNwdWm2YX70JIhq\2incjDs[ZZmdHNib3[gZYN1cX[nLDD1cpBpd3OyaH;yfYxifGWmLDFOtk1k[XSnbnnu MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4NkC2N{c,OjV{Nk[wOlM9N2F-
SK-N-AS  MVHGeY5kfGmxbjDBd5NigQ>? MYqxNEDPxE4EoB?= NX;CS4poOjRiaB?= MV7pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gZ5lkdGmwIFSx MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4NkC2N{c,OjV{Nk[wOlM9N2F-
SK-N-AS  M3;xRWZ2dmO2aX;uJGF{e2G7 NVXUNFltOTBizszNxsA> NUTKU41OOjRiaB?= MnHxbY5kemWjc3XzJJRp\SClQV3QJIxmfmWuc9Mg NFHPelg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2OlA3Oyd-MkWyOlYxPjN:L3G+
SK-N-AS  M4DXN2NmdGxiVnnhZoltcXS7IFHzd4F6 MXixNEDPxE4EoB?= MWqyOE81QCCq NYrseG5u\W6qYX7j[ZMhfGmvZT3k[ZBmdmSnboTsfUBk\WyudXzhdkB3cWGkaXzpeJnDqA>? MojyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{Nk[wOlMoRjJ3Mk[2NFY{RC:jPh?=
granulosa cells MYXGeY5kfGmxbjDBd5NigQ>? M{PmZVExKM7:TR?= Mmr4NlQhcA>? MoPJbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiUlfTNkBxem:vb4TldkBi[3Srdnn0fS=> M2PhUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O5NVA2Lz5{NUOzPVExPTxxYU6=
granulosa cells MYjGeY5kfGmxbjDBd5NigQ>? MVexNEDPxE1? MkjxNlQhcA>? MV;pcoNz\WG|ZYOgeIhmKGmwdHXud4l1gSCxZjDEUmEweHKxdHXpckBkd22ybHX4 MnTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|M{mxNFUoRjJ3M{O5NVA2RC:jPh?=
granulosa cells M4fhOmZ2dmO2aX;uJGF{e2G7 NYnRSow5OTBizszN NV33dXMzOTJxMkSgbC=> M3uxS4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIILldI9zfGW{IHHjeIl3cXS7IH\vdkB1cGVibH;u[4V{fCCocnHncYVvfCBq4pkSPFU1NytzOGLHV|IvVFWFKR?= MmnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|M{mxNFUoRjJ3M{O5NVA2RC:jPh?=
granulosa cells Mm[wSpVv[3Srb36gRZN{[Xl? NVHTV45COTBizszN NYrM[ZpFOTJxMkSgbC=> M13nT4lv[3KnYYPld{B1cGVibHX2[Yx{KG:owrDSS3MzyqCvUl7B MoDZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|M{mxNFUoRjJ3M{O5NVA2RC:jPh?=
BeWo  MnHZSpVv[3Srb36gRZN{[Xl? NGXhOpczOMLiwsXN NW\2U45JPDkEoHlCpC=> M4fPb2ROW00EoB?= M{jyO4Rwf26{ZXf1cIF1\XNidHjlJIxmfmWuIH;mJGdEVS1z MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4MkK2NEc,OjV|NkKyOlA9N2F-
BeWo  M3nXcmZ2dmO2aX;uJGF{e2G7 Mo\FNlDDqML3TR?= NIrHPVg1QMLiaNMg Mor5SG1UV8Li MkfS[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wxib3[gWG1GVUZzNh?= NHL1e5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2NlI3OCd-MkWzOlIzPjB:L3G+
BeWo  M3fMNGZ2dmO2aX;uJGF{e2G7 MmKwNlDDqML3TR?= M{e0UlQ5yqCqwrC= MVfEUXNQyqB? NWPlfW04cW6lcnXhd4V{KHSqZTDi[ZRiNWiFRzDy[Yxm[XOn M{joblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[yNlYxLz5{NUO2NlI3ODxxYU6=
EM1  Mnn0SpVv[3Srb36gRZN{[Xl? NVPZ[ZE3OTYkgJtOwG0> MlTpOFghcA>? NGjaN2dz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBNUUcEoH;yxsBRXEeVMtMgbY7DqEODTGKtJI9zyqCHUFHDNk1{cWynbnPl[EBGVTFiY3XscJPDqA>? NIKyfFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3PFY3OSd-MkWzO|g3PjF:L3G+
Primary bovine chondrocytes Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXQ[XRyPc7:TR?= MmnDOFghcA>? MX7y[ZZmenOnczD0bIUhcW6qaXLpeI9zgSCnZn\lZ5Qhd2ZiY3Xs[YNwgGmkIH;uJJBzd2yrZnXyZZRqd25iaX6g[5Jwf3SqIIDsZZRmKGOqb37kdo9kgXSncx?= M4fqR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEC2NFE3Lz5{NUSwOlAyPjxxYU6=
RBMECs NFSzPXpHfW6ldHnvckBCe3OjeR?= Mn7GOeKh|ryP MYGxJIg> MmfQZoxw[2u|IITo[UBi[3SrbjDjfZRwe2unbHX0c44hemWjcoLhcodmdWWwdDDz[YVvKHerdHigSW1CWC2LSTD0doVifG2nboVCpC=> M3rsRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs NInM[FZHfW6ldHnvckBCe3OjeR?= MlPMOeKh|ryP NV7Be4JwOSCq M37aXIJtd2OtczD0bIUhTU2DUD3JTU1qdmS3Y3XkJINp[W6pZTDpckBOVENicHjvd5Bpd3K7bHH0bY9v MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
RBMECs MYLGeY5kfGmxbjDBd5NigQ>? MoXEOeKh|ryP MX:xJIg> M4nFXpJmfmW{c3XzJJRp\SClaHHu[4V{KGmwIGrPMVEh\Gm|dILpZpV1cW:wIIPl[Y4hf2m2aDDFUWFRNUmLIITy[YF1dWWwdB?= NImwbnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxOlY2OSd-MkW0NVY3PTF:L3G+
RBMECs Mk\tSpVv[3Srb36gRZN{[Xl? MXq1xsDPxE1? M1XvcVEhcA>? NFTzNVdqdmirYnn0d{B1cGViZHXjdoVie2WmIH;mJIFud3WwdDDv[kBbVy1zIHnuJG1HeyCrbnT1Z4VlKGK7IFXNRXAuUUl? NV\3NFhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
RBMECs NYnGXZVjTnWwY4Tpc44hSXO|YYm= M{f6W|XDqM7:TR?= MVSxJIg> NIG3XZNxemW4ZX70d{B1cGViaX7jdoVie2ViaX6gTHJRKG[udYigZYNzd3O|IITo[UBDXEJiaX7keYNm\CCkeTCgSW1CWC2LSR?= M4fYWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs M1zNUWZ2dmO2aX;uJGF{e2G7 NWTxTmJQPcLizszN M1riflEhcA>? M2\BUJBz\X[nboTzJJRp\SCHTVHQMWlKNWmwZIXj[YQhXEWHUjD2ZYx2\SCmZXPy[YF{\Q>? NH7WVos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxOlY2OSd-MkW0NVY3PTF:L3G+
RBMECs NUO4U4J2TnWwY4Tpc44hSXO|YYm= NX3JUGJbPcLizszN NUHselUzOSCq MonIZoxw[2u|IITo[UBi[3SrdnH0bY9vKG:oIGLoc2EwWk:FSzDpcoR2[2WmIHL5JGVOSVBvSVm= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
RBMECs MkjpSpVv[3Srb36gRZN{[Xl? NXr1eFBrOC5yNT:wMlUwPSEQvF2= NHHuenoxNjJ3IHi= NX\qTFlDcW6lcnXhd4V{KGODTWCgZ49v[2WwdILheIlwdg>? M1y5TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
ThGCs  NFvxeYxHfW6ldHnvckBCe3OjeR?= MWmxNQKBks7:TR?= MlKzN{Bp NFH0ZoNqdmirYnn0d{B1cGViZX\m[YN1KG:oIFiyU|Ihd25iRVTONkBuWk6D Mnu2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{OwNlcoRjJ3NEOzNFI4RC:jPh?=
ThGCs  MYfGeY5kfGmxbjDBd5NigQ>? MWmxNQKBks7:TR?= MYK05qCLcA>? M{Oy[Ylv[3KnYYPld{BEd0OuMj3pcoR2[2WmIFXEUlLDqGenbnWg[ZhxemW|c3nvci=> MmrPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{OwNlcoRjJ3NEOzNFI4RC:jPh?=
ThGCs  NX\Ye4NlTnWwY4Tpc44hSXO|YYm= MmfONVDjiIsQvF2= NVz2c4pqPOLCini= MV3heYdu\W62czDITWYySSCuZY\lcJMhfGijdDD3[ZJmKHO2aX31cIF1\WRiYomgR49EdDJ? NILZOHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzN|AzPyd-MkW0N|MxOjd:L3G+
LNCaP  MWDGeY5kfGmxbjDBd5NigQ>? NHX2fIMyOMLizszN M1HBNVEzKGkEoB?= NYK1U3BVTE2VTx?= NYDTPXRycW6mdXPld{BiKGS{YX3heIlkKGmwY4LlZZNmKG:oIFPSSWIyKGGldHn2bZR6 NI\Weo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW0PFA6QSd-MkW1OFgxQTl:L3G+
BeWo NWPiS4sxTnWwY4Tpc44hSXO|YYm= M3rrZ|IxyqEEtV2= NUeyN2F1PDkEoHi= NWfHeVZoTE2VTx?= NF;re5NqdmO{ZXHz[ZMhfGinIHHkbIV{cW:wIH;mJHRJWC1zIH3vco9kgXSncx?= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4Nke0NEc,OjV3Nk[3OFA9N2F-
BeWo MlvJSpVv[3Srb36gRZN{[Xl? NXjvdFR[OjEEoNM1US=> MoXXOFjDqGh? NVfPWnVWTE2VTx?= NXf5cFNrcW6lcnXhd4V{KHSqZTDkbYZn\XKnboTpZZRqd25ib3[gRoVYdyClZXzsdy=> Mkf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3Nk[3OFAoRjJ3NU[2O|QxRC:jPh?=
OCI-Ly18  MWnGeY5kfGmxbjDBd5NigQ>? MlHTOFDDqM7:TR?= M{HRblHDqGkEoB?= NHW0fmhFVVOR NFfHd41qdmS3Y3XzJJRp\SCrbnPy[Y1mdnRib3[gZ2FOWCClb37j[Y51emG2aX;udy=> MnK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3N{[yNlAoRjJ3NUe2NlIxRC:jPh?=
OCI-Ly1  MlTTSpVv[3Srb36gRZN{[Xl? NYLsSZhuPDEEoN88US=> NWLKOJBXOcLiaNMg MYDEUXNQ MUjpcoR2[2W|IITo[UBqdmO{ZX3lcpQhd2ZiY1HNVEBkd26lZX70doF1cW:wcx?= MlnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3N{[yNlAoRjJ3NUe2NlIxRC:jPh?=
3T3-L1 MkTvSpVv[3Srb36gRZN{[Xl? NV7KW5k2Oi53L{Wg{txO NH7qRWYzPCCqwrC= M{GxSZNq\26rZnnjZY51dHliZHXjdoVie2W|IFHUS2wheHKxdHXpckBmgHC{ZYPzbY9vKGG2IHHscEBld3OnczD0[ZN1\WR? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7MEW5O{c,OjV3OUC1PVc9N2F-
HEK293  NYfDOHB3TnWwY4Tpc44hSXO|YYm= NXnC[pFqPeLCidM1US=> MXizNEBucW5? MWDpcoNz\WG|ZYOgZ2FOWCCuZY\lcJM> NX\ySJA1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVE6ODhpPkK1OVkyQTB6PD;hQi=>
hADSCs NY\LflZ5TnWwY4Tpc44hSXO|YYm= MkjGOgKBkcL3TR?= NIfjSG4{OCCvaX6= NGnofotqdmO{ZXHz[ZMh[0GPUDDs[ZZmdHN? MmXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUG5NFgoRjJ3NUmxPVA5RC:jPh?=
SH-SY5Y  NIfBeYdHfW6ldHnvckBCe3OjeR?= NY\PbGhROTEEoN88US=> NWLyc4Z5OcLiaNMg MYfpcoNz\WG|ZYOgRWdEOSCvUl7BJIxmfmWu NWfMTHU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVc1OzNpPkK1OVk4PDN|PD;hQi=>
SH-SY5Y  NGWwU5VHfW6ldHnvckBCe3OjeR?= NXr3W3o4OTEEoN88US=> NFjEfZIyyqCqwrC= MVXpcoNz\WG|ZYOgUHVEKGGldHn2bZR6 NX;JTolxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVc1OzNpPkK1OVk4PDN|PD;hQi=>
UACC-647  MmK1SpVv[3Srb36gRZN{[Xl? NF\vUWoyOMLizszN NWDDdGxrOTVibXnu M{C2XGROW09? M36xR4lv[3KnYYPld{BmTUZ{IIDoc5NxcG:{eXzheIlwdiCuZY\lcJPDqA>? MljHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEOwNlUoRjJ3N{CzNFI2RC:jPh?=
UACC-647  NYDzWFB7TnWwY4Tpc44hSXO|YYm= NF7BUI8yOMLizszN MWexOUBucW5? MXHEUXNQ MnmxbY5pcWKrdIOgSXJMKHCqb4PwbI9zgWyjdHnvci=> NWXuXWt[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFMxOjVpPkK1O|A{ODJ3PD;hQi=>
UACC-647  MoDnSpVv[3Srb36gRZN{[Xl? NFyzeFZFVVOR M{X1Woxm[WS|IITvJIEhemm|ZTDpckBkSU2SIHzleoVteyBqRVO1NOKhRcLiMkCuN|nDqM7:TTm= M3iwc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CzNFI2Lz5{NUewN|AzPTxxYU6=
SC MUHGeY5kfGmxbjDBd5NigQ>? M4LhN|AvPSEQvF2= M2\W[VczKGh? NFHWdW9qdmO{ZXHz[ZMh[m:2aDDLdo95NTJyIHHu[EBQOSCneIDy[ZN{cW:wIHnuJIF5d25vcnXsZZRm\CCVQ4OgZpV1KG:wbImgT5JwgC1{MNMg Moe3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEW4O|QoRjJ3N{C1PFc1RC:jPh?=
SC NWrRWoM{TnWwY4Tpc44hSXO|YYm= MoiwNE42KM7:TR?= NVjKfWljOjRiaB?= M2fKS41qdWmla4OgeIhmKGWoZnXjeEBw\iClQV3QJIFv[WyxZ4Ogc44hVzFiYX7kJG1DWCCneIDy[ZN{cW:w NG\GR2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUewOVg4PCd-MkW3NFU5PzR:L3G+
oocytes M3rCeGZ2dmO2aX;uJGF{e2G7 M2fOS|Uh|ryP M3fGWVI1KGh? MVLheJRmdnWjdHXzJJJpNWmwc4XsbY4h[WO2aX;uJI9vKG:xY4n0[UBIXkKGIIPp[45q\mmlYX70cJnDqA>? MlXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEe4OVQoRjJ3N{C3PFU1RC:jPh?=
BeWo MWrGeY5kfGmxbjDBd5NigQ>? NHezU28yOOLCit88UeKh NG\Pfo04OiCq MlvOSG1UVw>? NUDPVppidWWmaXH0[ZMhSmWZbzDj[YxtKGSrZn\ldoVvfGmjdHnvci=> M3\yNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{GzOFI2Lz5{NUexN|QzPTxxYU6=
GH3 M1WwT2Z2dmO2aX;uJGF{e2G7 Mmf1NeKh|ryP MofXOk1p MkP0bY5lfWOnczDQVmwh[W6mIFLtZYwyNCCkdYSgco91KEOub3PrMEBuWk6DIHX4dJJme3Orb36= NIfxPWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO|AyQCd-MkW3NlcxOTh:L3G+
GH3 NETTXIZHfW6ldHnvckBCe3OjeR?= M1XUUFHDqM7:TR?= MnHCOk1p MmjGZZR1\W63YYTld{B1cGViY3;ydoVt[XSrb36gZoV1f2WnbjDQVmwh[W6mIFLtZYwyKGW6cILld5Nqd25? NFiyNHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO|AyQCd-MkW3NlcxOTh:L3G+
PC12 MoH0SpVv[3Srb36gRZN{[Xl? M4DwZ|I2yqEQvF2= NYCwSWRFPDhiaB?= NUGyUmRq[WO2aY\heIV{KGODTWC= NUHEWIpyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3Olk{ODVpPkK1O|Y6OzB3PD;hQi=>
BAECs MVLGeY5kfGmxbjDBd5NigQ>? MkPiNlUh|ryP NFG2NIUzPCCq MonC[Y5p[W6lZYOgeIhmKGGldHn2ZZRqd25ib3[gVHBCWs7zIHL5JFUh|ryPIILld5ZmemG2cn;sMEBVPEiVLDDvdkA1NVCDUB?= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7OEiyOkc,OjV5OUi4NlY9N2F-
GLUTag  M1fEWmZ2dmO2aX;uJGF{e2G7 M{LwTVEx6oDLwsXN MX:0JIg> M4PqVYlv[3KnYYPld{B1cGVicFPSSWIhdGW4ZXzzJJdqfGhidHjlJGlDVVh? NH;TTIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizNlY{OSd-MkW4N|I3OzF:L3G+
GLUTag  MmfiSpVv[3Srb36gRZN{[Xl? M3vuOlEx6oDLwsXN M4rvOFAwOi92IHi= M3fSXpN1cW23bHH0[ZMhT0ySLUGgd4VkemW2aX;uJINwfHKnYYTl[EB4cXSqIFnCUXg> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh|Mk[zNUc,OjV6M{K2N|E9N2F-
PBMC M{mwTGZ2dmO2aX;uJGF{e2G7 Mk\sOVDDqM7:TR?= NGPQWI8zPMLiaNMg NXP6S5JWcW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDz[YNz\XSrb36gc4YhXE6IIHnu[JVk\WRiYomgeIhmKESSRR?= NUfaOnQzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlYxPzlpPkK1PFY3ODd7PD;hQi=>
H295R  NXTyPJhKTnWwY4Tpc44hSXO|YYm= NHLTV5AyOMLizszN M1fseVQ5yqCq NXTLWoVucW6lcnXhd4V{KHO2ZYLvbYQhdWW2YXLvcIl1\XNiaX6geIhmKGGwZILv[4VvNCCvaX7ldoFtdy1iYX7kJIdtfWOxY3;yeIlkd2mmIIDheIh4[Xm| NF3BVFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi2PVU2Pid-MkW4Olk2PTZ:L3G+
3T3-L1 preadipocytes NX\TWWJPTnWwY4Tpc44hSXO|YYm= MU[xNEDPxE4EoB?= NFXUXFMyOiCq MnvEbY5lfWOnczDDVmVDKHCqb4PwbI9zgWyjdHnvckBidmRiQz;FRnDPuiCneIDy[ZN{cW:w NUH1WG46RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NlgxPThpPkK1PVI5ODV6PD;hQi=>
PCCL3 MnrXSpVv[3Srb36gRZN{[Xl? NXfhNG9pOTBiwsXN NInHVZozPCCq MYHlcohidmOnczDEeW95OiCycn;tc5RmeiC2cnHud4NzcXC2aX;uJIFkfGm4aYT5xsDjiIt? M1eweFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wPVU3Lz5{NUm2NFk2PjxxYU6=
SCG NFT0co5HfW6ldHnvckBCe3OjeR?= NFPTR2UyODBizszNxsA> M3;1TGROW09? M4HQUZJm\HWlZYOgeIhmKGW6Y3n0ZYJqdGm2eTDv[kBUS0dibnX1do9vew>? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MkGzNkc,OjV7NkKxN|I9N2F-
HEK-293 NEfnTWFHfW6ldHnvckBCe3OjeR?= NIfBcZc{PSEQvF5CpC=> NXizeGE3TE2VTx?= M3u3UYlv\HWlZYOgZUBkd26|cHnjeY92eyEkgKzpcoFkfGm4YYTpc47jiJ1ib3[geIhmKEu4Mj6xJIN2enKnboS= M3f0cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[yNVMzLz5{NUm2NlE{OjxxYU6=
SCG M2rZdWZ2dmO2aX;uJGF{e2G7 M4nGPFIxKM7:TdMg MnzpSG1UVw>? MV3y[ZZmenOrYnz5JJN2eHC{ZYPz[ZMhUUuYIIfpeIgh[SCLQ{WwJI9nKDJ2LkSg{txO NXnsZZpIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlIyOzJpPkK1PVYzOTN{PD;hQi=>
PC-3 M2i0WmNmdGxiVnnhZoltcXS7IFHzd4F6 NEXtPHQ1OCEEtV2= NYPRbmJrOjRxNEivO|IhcA>? NIftZlVFVVOR MkXW[IVkemWjc3XzJINmdGxidnnhZoltcXS7IITpcYUh\GWyZX7k[Y51dHl? MmXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkO4N|YoRjJ4MEKzPFM3RC:jPh?=
PC-3 MX3GeY5kfGmxbjDBd5NigQ>? NGrVRmo1OCEEtV2= MWWyJIg> NH3IVWJFVVOR MlPBcIVi\HNidH:gVHAzSSCjY4TpeoF1cW:w MoXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkO4N|YoRjJ4MEKzPFM3RC:jPh?=
SH-SY5Y M{LGfmZ2dmO2aX;uJGF{e2G7 NWrEc4hQOzBizszN MlrwN|AhdWmw MnrkSG1UVw>? M1vlRZNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBi[3SrdnH0bY9vKG:oIGDLRS=> NGLNZWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyOVE{Pyd-Mk[wNlUyOzd:L3G+
EndoC-βH1 MYfGeY5kfGmxbjDBd5NigQ>? Ml;rOeKh|ryP MnXpNUBp MnTRcIVi\HNidH:gZUB{fHKxbnegZ2FOWCCrbnPy[YF{\Q>? NFvmcJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyPFU3Oid-Mk[wNlg2PjJ:L3G+
EndoC-βH1 NEKxcmpHfW6ldHnvckBCe3OjeR?= NIDUUW82yqEQvF2= M1nGT|EhcA>? MmjwdI91\W62aXH0[ZMh\2y3Y3;z[U1qdmS3Y3XkJIlve3WuaX6gd4VkemW2aX;uJIlvKHSqZTDwdoV{\W6lZTDv[kBodHWlb4Pl MkLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMki1OlIoRjJ4MEK4OVYzRC:jPh?=
RBMECs MYrGeY5kfGmxbjDBd5NigQ>? NUTpOllQPcLizszN MoXnNUBp MmLabY5pcWKrdIOgSW1CWC2LST3pcoR2[2WmIHnuZYN1cX[jdHnvckBw\iCUYYCxxsA> M2PW[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES0OlY{Lz5{NkC0OFY3OzxxYU6=
AML-12  MXnGeY5kfGmxbjDBd5NigQ>? M124PFIxKM7:TR?= NGT0eYQ{KGh? MWjpcoR2[2W|IITo[UBl\XCqb4PwbI9zgWyjdHnvckBw\iCFUmTDNuKh MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2OEm4OUc,OjZyNEi5PFU9N2F-
AML-12  MlPYSpVv[3Srb36gRZN{[Xl? MmTTNlAh|ryP M2S5WlMhcA>? MmP4eZAuemWpdXzheIV{yqCSZ3OxZUzDqFCncHPrMEBidmUEoFe2dIPDqG2UTlGgcIV3\Wy| NF71Oms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0PFk5PSd-Mk[wOFg6QDV:L3G+
AML-12  NYOybXFZTnWwY4Tpc44hSXO|YYm= NXO2UIh2OjBizszN MkG2NU05KGh? MmjxbY5kemWjc3XzJIdtfWOxc3WgdJJw\HWldHnvci=> MoPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEi5PFUoRjJ4MES4PVg2RC:jPh?=
AML-12  MmLsSpVv[3Srb36gRZN{[Xl? NGnNUYMzOCEQvF2= NF7xeoM{KGh? MXT1dJJm\3WuYYTld{B1cGVicHjvd5Bpd3K7bHH0bY9vKGyndnXsd{BifCCWaIKtOFEyKGGwZDDT[ZIuPDl| NXTNW4lXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFg6QDVpPkK2NFQ5QTh3PD;hQi=>
Caco-2  M17oc2Z2dmO2aX;uJGF{e2G7 MUWwMlEwOS9zMDFOwG0> NVTueJBoOjRiaB?= NHP3d3JqdmO{ZXHz[ZMhVVKSMjDwdo91\WmwIHzleoVt NHzQUmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0PVExOid-Mk[wOFkyODJ:L3G+
Caco-2  NW\aZlhHTnWwY4Tpc44hSXO|YYm= MWKwMlEwOS9zMDFOwG0> M3HXUVIxyqCvaX6= MWHpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClQV3QJIxmfmWucx?= Mnr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEmxNFIoRjJ4MES5NVAzRC:jPh?=
bovine oocytes MmnrSpVv[3Srb36gRZN{[Xl? NIT2[WkyODEEoN88US=> NGXUXWsyOsLiaB?= Mn\5bY5pcWKrdIOgeIhmKGWoZnXjeEBw\iCQUGDBJIFv\C:xcjDOVHBEKHSxIIP0bY12dGG2ZTDy[ZN2dXC2aX;uJI9nKG2naX;zbZM> MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3MU[xNUc,OjZyNUG2NVE9N2F-
BeWo  MmXRSpVv[3Srb36gRZN{[Xl? MmjuNlXjiIoQvF2= NHTLWFUzPC92OD:3NkBp NUHoZnk1dGWjZIOgeI8h[W5iaX7jdoVie2ViaX6geIhmKGW6cILld5Nqd25ib3[gc5Rp\XJiZoXzbY9vKG2jcnvldpM> MnfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUO1OFkoRjJ4MEWzOVQ6RC:jPh?=
Spinal cords  M4LsTWZ2dmO2aX;uJGF{e2G7 MVOxxsDPxE1? NXLWOVFuOzBibXnu M4D5XpN1cW23bHH0[ZMh[0GPUDDs[ZZmdHN? NUjhbWlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlY6OjZpPkK2NVI3QTJ4PD;hQi=>
MDCK  NFKycVlHfW6ldHnvckBCe3OjeR?= NGjQbHQyOCEEtV2= MoDWNlQhcA>? M3PxSmROW09? MmP5bY5pcWKrdIOgeIhmKGmwY4LlZZNm\CCneIDy[ZN{cW:wIH;mJGZPKGOjdYPl[EBjgSCWR1[t{tIy NHS5dIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKwNlM2Oid-Mk[yNFI{PTJ:L3G+
MDCK  MYfGeY5kfGmxbjDBd5NigQ>? NFnHOlQyOCEEtV2= M2[0cFI1KGh? M{GxfWROW09? M2W1XZVxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKFSJRj5OtlEh[W6mIFPUS2bDqA>? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJyMkO1Nkc,OjZ{MEKzOVI9N2F-
RPMI 8226 NYqySW43S2WubDDWbYFjcWyrdImgRZN{[Xl? NVTZ[XFxOC1zMECg{txO M2rQ[lcz6oDLaB?= NYX1SG81cW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> M3fDO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{C2OlI1Lz5{NkOwOlYzPDxxYU6=
H929 MkToR4VtdCCYaXHibYxqfHliQYPzZZk> NYLQbWtrOC1zMECg{txO MX63NwKBkWh? MnT5bY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= MnjmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|ME[2NlQoRjJ4M{C2OlI1RC:jPh?=
U266 M4LSc2NmdGxiVnnhZoltcXS7IFHzd4F6 NE\LR5QxNTFyMDFOwG0> M{nBOVcz6oDLaB?= NEH1blNqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> Ml3yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|ME[2NlQoRjJ4M{C2OlI1RC:jPh?=
OPM-2 M{G5OmNmdGxiVnnhZoltcXS7IFHzd4F6 M1HielAuOTByIN88US=> M2nwe|cz6oDLaB?= MX;pcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= MnXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|ME[2NlQoRjJ4M{C2OlI1RC:jPh?=
INA-6 M17Se2NmdGxiVnnhZoltcXS7IFHzd4F6 NYPxO5E3OC1zMECg{txO MoPmO|LjiImq NYrwc5RlcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> M1XscFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{C2OlI1Lz5{NkOwOlYzPDxxYU6=
RBMECs  M3[4[WZ2dmO2aX;uJGF{e2G7 M{HiW|XDqM7:TR?= NFTocpMyyqCq NW\WNGl6[myxY3vzJJRp\SCUYXOxJIlv[WO2aY\heIlwdiCrbnT1Z4VlKGK7IFXNRXAuUUl? MmO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NUiwN|koRjJ4M{W4NFM6RC:jPh?=
Mo-DCs M2THNWZ2dmO2aX;uJGF{e2G7 MXy1NEDPxE1? NH7aRXgzPOLCiXi= MlvIdJJwdW:2ZYOgTWwuOjNicILv[JVkfGmxbjDpckB1cGVic4Xw[ZJv[XSjboSgc4Yhgnmvb4PhckB{fGmvdXzheIVlKE2xLVTDd:Kh MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjRzMkm0PEc,OjZ2MUK5OFg9N2F-
HEK293 Ml\6SpVv[3Srb36gRZN{[Xl? M4HQUFExKM7:TR?= NGi3WnE3KGh? MlrybY5kemWjc3XzJJBpd3OyaH;yfYxifGmxbjDv[kBwfmW{ZYjwdoV{e2WmIFvMTGw{KGG2IGO0N|M> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR|NUS5PEc,OjZ2M{W0PVg9N2F-
ASK MnjOSpVv[3Srb36gZZN{[Xl? Mn3iNUBpeg>? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR7NkSxK|4zQDR7NkSxQE9iRg>?
Vero E6 NHLzNJVCdnSrdnnyZYwh[XO|YYm= MmjOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4NkO1N|koRjF5Nk[zOVM6RC:jPh?=
epithelial cells NHHOd2ZHfW6ldHnvckBie3OjeR?= M1ToXFEhfU1? MlzLOEwhPixiYX7kJFgh\GG7cx?= NU[5SYM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OlY4QDlpPkG5PVY3Pzh7PD;hQi=>
HepG2 (DPX-2) NXv0UIZFTnWwY4Tpc44h[XO|YYm= M2HhelI1KGi{cx?= M4S5[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOU[2NFQ{Lz5{MEm2OlA1OzxxYU6=
HepG2 M2PDNGZ2dmO2aX;uJIF{e2G7 MYSyOEBpenN? MoG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7Nk[wOFMoRjJyOU[2NFQ{RC:jPh?=
HepG2 (DPX-2) NGPudYNHfW6ldHnvckBie3OjeR?= NVuwOo1qOjRiaILz MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl4NkC0N{c,OjB7Nk[wOFM9N2F-
HEK293T M2nIfGZ2dmO2aX;uJIF{e2G7 NWr0b4NGOTBidV2= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN6N{OyOUc,OjR|OEezNlU9N2F-
HEK293 NULvXYdSTnWwY4Tpc44h[XO|YYm= NYD0SZhHOTBidV2= MW[xOkBpenN? NXzocHdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0N|U2OTJpPkK2OFM2PTF{PD;hQi=>
MCF7 MknQR5l1d3SxeHnjbZR6KGG|c3H5 MlXGOFghcHK| NXrhbHU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4N|g3QTJpPkK4PFM5Pjl{PD;hQi=>
HEK293 M3zJcGZ2dmO2aX;uJIF{e2G7 NW\WSok2OzBibXnudy=> MnfDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xO|YoRjNyMEC2NVc3RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Water Insoluble
Ethanol ''37 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 410.5
化学式

C22H34O7

CAS号 66575-29-9
储存条件 粉状
溶于溶剂
别名 Coleonol, Colforsin

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04254705 Not yet recruiting Procedure: Rectal Biopsy Cystic Fibrosis Universitaire Ziekenhuizen Leuven|Vertex Pharmaceuticals Incorporated|KU Leuven|University of Lisbon March 1 2020 Not Applicable
NCT02807415 Completed Drug: Lumacaftor plus Ivacaftor Cystic Fibrosis Hannover Medical School|Heidelberg University|University of Giessen June 1 2016 --
NCT02586883 Completed Other: bronchial ddp test Idiopathic Dilation of the Bronchi Assistance Publique - Hôpitaux de Paris March 29 2016 Not Applicable
NCT03652090 Completed Procedure: cell sampling Cystic Fibrosis Institut National de la Santé Et de la Recherche Médicale France|ABCF2 September 1 2010 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

cAMP Signaling Pathway Map

Tags: 购买Colforsin (Forskolin, HL 362) | Colforsin (Forskolin, HL 362)供应商 | 采购Colforsin (Forskolin, HL 362) | Colforsin (Forskolin, HL 362)价格 | Colforsin (Forskolin, HL 362)生产 | 订购Colforsin (Forskolin, HL 362) | Colforsin (Forskolin, HL 362)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID